A Study to Examine the Efficacy and Safety of Posaconazole When Introduced Early in the Treatment of Refractory Fungal Infections (P05090 AM2)

Mycoses Clinical Trial

— TIP  

Official title:

A Phase II Study on Treatment of Refractory Fungal Infections With Posaconazole. The "TIP" Study.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00550732
• Other study ID #: P05090
• Status: Completed
• Phase: Phase 2
• First received: October 29, 2007
• Last updated: August 4, 2015
• Start date: December 2007
• Est. completion date: November 2012

Study information

• Verified date: August 2015
• Source: Merck Sharp & Dohme Corp.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of posaconazole in the early treatment of fungal infections in participants who are refractory to, intolerant to, or medically precluded from first-line monotherapy or first-line combination antifungal therapy.

Description:

In the past two decades, invasive fungal infections (IFI) have become increasingly common among immunocompromised people, including solid-organ or hematopoietic stem-cell transplant recipients, those with HIV infection, those with hematological malignancies, and individuals on immunosuppressive drug regimens. There is a high rate of morbidity and mortality associated with IFI. Over the past decade, there has been an increase in resistance to commonly used antifungal agents and an epidemiological shift to more drug-resistant strains. This has demonstrated the need for the development of a new generation of azoles.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: November 2012
• Est. primary completion date: November 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 13 Years and older

Eligibility

Inclusion Criteria:

• Proven or probable invasive fungal infection (IFI) including breakthrough infection while on antifungal treatment for at least 7 days.

• Refractory or intolerant to prior antifungal therapy, or medically unable to receive standard antifungal therapy.

• Age =13 years old.

• Expected to survive >1 month.

• Negative pregnancy test (serum or urine) at baseline for women of childbearing potential.

Exclusion Criteria:

• Serum bilirubin >10 times upper limit of normal (ULN).

• Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >10 times ULN.

• Documented allergy to azoles.

• Unable to take oral suspension medications or enteral feeding.

• Pregnant or breastfeeding.

• Participants who have received an investigational drug are allowed to be enrolled if the investigational drug was given 30 days prior to study registration, unless approved by the Sponsor.

• Requires surgery.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Mycoses

Intervention

Drug:
• Posaconazole
Posaconazole oral suspension was administered as 400 mg twice daily (bis in die, BID) with food or 200 mg four times daily (quater in die, QID) without food for a minimum of 1 month.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Merck Sharp & Dohme Corp.	JSS Medical Research Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Complete Response (CR) or Partial Response (PR) by 12 Weeks or End of Treatment	Complete Response was defined as resolution of all attributable clinical signs and symptoms and radiologic and mycologic abnormalities, if present at baseline. Partial Response was defined as clinically meaningful improvement in attributable clinical signs and symptoms and radiologic and mycologic abnormalities, if present at baseline.	Up to 6 months	No
Secondary	Number of Participants With =50% Decrease in Lesion Size or Number	Reduction in lesion size was analyzed by computed tomography (CT) scan. An imaging response was defined as >=50% reduction in lesion size for pulmonary and cerebral disease or >=50% reduction in the number of lesions for liver disease.	Up to 6 months	No
Secondary	Percentage of Participants With a CR or PR by 12 Weeks	Complete Response was defined as resolution of all attributable clinical signs and symptoms and radiologic and mycologic abnormalities, if present at baseline. Partial Response was defined as clinically meaningful improvement in attributable clinical signs and symptoms and radiologic and mycologic abnormalities, if present at baseline.	Up to 12 Weeks	No
Secondary	Percentage of Participants With CR or PR by 4 Weeks and by 26 Weeks	Complete Response was defined as resolution of all attributable clinical signs and symptoms and radiologic and mycologic abnormalities, if present at baseline. Partial Response was defined as clinically meaningful improvement in attributable clinical signs and symptoms and radiologic and mycologic abnormalities, if present at baseline.	Up to 26 weeks	No
Secondary	Percentage of Participants With Infection-free Survival After the Last Dose of Study Drug	Infection-free survival was the proportion of evaluable participants included in the efficacy analysis who are infection-free and alive at 6 months post last dose visit. Infection-free is defined as the resolution of signs and symptoms of infection.	Up to 6 months	Yes
Secondary	Overall Survival at 3 Months	Total number of participant survivors was assessed at 3 months.	3 months	Yes
Secondary	Number of Participants With Response to Posaconazole in Combination Therapy	Complete Response was defined as resolution of all attributable clinical signs and symptoms and radiologic and mycologic abnormalities, if present at baseline. Partial Response was defined as clinically meaningful improvement in attributable clinical signs and symptoms and radiologic and mycologic abnormalities, if present at baseline.	Up to 6 months	No
Secondary	Number of Participants Experiencing Adverse Events (AEs)	An adverse event (AE) is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the study drug.	Up to 12 months	Yes